SavedAdd your journal

Journals / Turkish journal of nephrology (Online) / 2022 / Cilt: 31 - Sayı: 1

Sarcopenia in Patients with Chronic Kidney Disease

Fatma Betül GÜZEL
Özkan GÜNGÖR
Kamyar Kalantar ZADEH
Sena ULU
Pages
3–6
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, general information about sarcopenia and the development of sarcopenia in patients with chronic kidney disease are discussed in light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sarcopenia is defined as a decrease in muscle mass and muscle strength, and its frequency increases with aging.
📊
Key Findings & Data:Since different criteria and methods can be used for its definition, its incidence rates vary.
💡
Conclusion & Impact:In this review, general information about sarcopenia and the development of sarcopenia in patients with chronic kidney disease are discussed in light of the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Sarcopenia is defined as a decrease in muscle mass and muscle strength, and its frequency increases with aging. Since different criteria and methods can be used for its definition, its incidence rates vary. Chronic kidney disease is a progressive process and many systems may be affected in these patients. Studies also show that chronic kidney disease can lead to the development of sarcopenia. Many factors are held responsible for the development of sarcopenia in chronic kidney disease. Age, inflammation, malnutrition, uremic toxins, and hormonal imbalance are the most important ones. In this review, general information about sarcopenia and the development of sarcopenia in patients with chronic kidney disease are discussed in light of the literature.

🔖

Cite This Article

GÜZEL, F. B., GÜNGÖR, Ö., ZADEH, K. K., ULU, S. (2022). Sarcopenia in Patients with Chronic Kidney Disease. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 1, 3–6. https://ajindex.com/articles/612810

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(suppl 5):990S-991S. [CrossRef]
  2. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the extended group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31
  3. Castillo-Olea C, Soto BG-Z, Lozano CC, Zuñiga C. Automatic classification of sarcopenia level in older adults: a case study at Tijuana General Hospital. IJERPH. 2019;16(18):3275. [CrossRef] 4. Kim H, Hirano H, Edahiro A, et al. Sarcopenia: prevalence and associated factors based on different suggested definitions in community-dwelling older adults. Geriatr Gerontol Int. 2016;16(suppl 1):110-122. [CrossRef] 5. Ábrigo J, Elorza AA, Riedel CA, et al. Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev. 2018;2018:2063179. [CrossRef] 6. Dalle S, Rossmeislova L, Koppo KK. The role of inflammation in age-related sarcopenia. Front Physiol. 2017;8:1045. [CrossRef] 7. Bachettini NP, Bielemann RM, Barbosa-Silva TG, Menezes AMB, Tomasi E, Gonzalez MC. Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European working group on sarcopenia in older people. Eur J Clin Nutr. 2020;74(4):573-580. [CrossRef] 8. Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347-1372. [CrossRef] 9. Souza VA, Oliveira D, Barbosa SR, et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: analysis of the prevalence and associated factors. PLoS One. 2017;12(4):e0176230. [CrossRef] 10. Bataille S, Chauveau P, Fouque D, Aparicio M, Koppe L. Myostatin and muscle atrophy during chronic kidney disease. Nephrol Dial Transplant. 2021;36(11):1986-1993. [CrossRef] 11. Pereira RA, Cordeiro AC, Avesani CM, et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol Dial Transplant. 2015;30(10):1718- 1725. [CrossRef] 12. Kim JK, Choi SR, Choi MJ, et al. Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin Nutr. 2014;33(1):64-68. [CrossRef] 13. Roshanravan B, Gamboa J, Wilund K. Exercise and CKD: Skeletal Muscle Dysfunction and Practical Application of Exercise to Prevent and